|
PE20100251A1
(es)
*
|
2004-09-10 |
2010-04-10 |
Wyeth Corp |
Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
|
|
US8008453B2
(en)
*
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
EP1790664A1
(en)
*
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against claudin-18 for treatment of cancer
|
|
BRPI0619476A2
(pt)
*
|
2005-12-05 |
2011-10-04 |
Wyeth Corp |
composições de interleucina-11 e métodos de uso
|
|
MY148763A
(en)
|
2006-03-10 |
2013-05-31 |
Wyeth Corp |
Anti-5t4 antibodies and uses thereof
|
|
CY1112212T1
(el)
*
|
2008-04-24 |
2015-12-09 |
Immatics Biotechnologies Gmbh |
Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
|
|
PT2113253E
(pt)
*
|
2008-04-30 |
2010-06-15 |
Immatics Biotechnologies Gmbh |
Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
|
|
AR076284A1
(es)
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
WO2011053763A2
(en)
|
2009-10-30 |
2011-05-05 |
Centocor Ortho Biotech Inc. |
Il-17a antagonists
|
|
EP2637692A4
(en)
|
2010-11-12 |
2014-09-10 |
Scott & White Healthcare |
ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
|
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
|
HUE045348T2
(hu)
|
2011-05-08 |
2019-12-30 |
Legochem Biosciences Inc |
Fehérje-hatóanyag konjugátumok és eljárás elõállításukra
|
|
RU2011132483A
(ru)
*
|
2011-08-02 |
2013-02-10 |
Елена Александровна Моренко |
Биологически активный продукт для применения в ветеринарии и животноводстве, способ его получения и способы повышения выживаемости, стимуляции роста, иммуностимуляции и повышения общей неспецифической резистентности организма сельскохозяйственных животных
|
|
CN104540518A
(zh)
|
2012-04-27 |
2015-04-22 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
US20130309223A1
(en)
*
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
US9493562B2
(en)
|
2012-07-19 |
2016-11-15 |
Alethia Biotherapeutics Inc. |
Anti-Siglec-15 antibodies
|
|
CN116574185A
(zh)
|
2012-07-25 |
2023-08-11 |
塞尔德克斯医疗公司 |
抗kit抗体及其用途
|
|
MX379256B
(es)
|
2013-03-15 |
2025-03-10 |
Regeneron Pharma |
Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
|
|
KR102252925B1
(ko)
|
2013-08-26 |
2021-05-18 |
리제너론 파마슈티칼스 인코포레이티드 |
마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
|
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
US9737623B2
(en)
|
2013-12-11 |
2017-08-22 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
AU2015229591B2
(en)
|
2014-03-11 |
2020-10-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-EGFRvlll antibodies and uses thereof
|
|
EA034950B1
(ru)
|
2015-03-27 |
2020-04-09 |
Регенерон Фармасьютикалз, Инк. |
Производные майтанзиноида, их конъюгаты и способы использования
|
|
AU2016286071A1
(en)
*
|
2015-06-29 |
2018-02-01 |
William Marsh Rice University |
Total synthesis of shishijimicin A and analogs thereof
|
|
MY189159A
(en)
|
2015-07-06 |
2022-01-29 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
EP3365025B1
(en)
|
2015-10-20 |
2020-07-15 |
Genentech, Inc. |
Calicheamicin-antibody-drug conjugates and methods of use
|
|
PT3380525T
(pt)
|
2015-11-25 |
2024-02-05 |
Immunogen Inc |
Formulações farmacêuticas e métodos que as utilizam
|
|
HRP20240795T1
(hr)
|
2015-11-25 |
2024-09-13 |
Ligachem Biosciences Inc. |
Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
|
|
JP2018536682A
(ja)
|
2015-12-11 |
2018-12-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
|
|
WO2017132173A1
(en)
|
2016-01-25 |
2017-08-03 |
Regeneron Pharmaceuticals, Inc. |
Maytansinoid derivatives, conjugates thereof, and methods of use
|
|
WO2017160954A1
(en)
|
2016-03-15 |
2017-09-21 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
|
|
CN105726527B
(zh)
*
|
2016-03-25 |
2018-05-11 |
苏州大学 |
小分子化合物的用途及其组合物
|
|
WO2017190079A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
WO2017210621A1
(en)
|
2016-06-03 |
2017-12-07 |
Seattle Genetics, Inc. |
Combination of cd33 antibody drug conjugates with chemotherapeutic agents
|
|
WO2017214433A1
(en)
|
2016-06-09 |
2017-12-14 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
|
|
WO2018002902A1
(en)
|
2016-07-01 |
2018-01-04 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Antibody-drug conjugates and therapeutic methods using the same
|
|
MX2019003325A
(es)
|
2016-09-23 |
2019-08-05 |
Regeneron Pharma |
Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos.
|
|
MY194596A
(en)
|
2016-09-23 |
2022-12-06 |
Regeneron Pharma |
Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates
|
|
KR20250114431A
(ko)
|
2016-11-08 |
2025-07-29 |
리제너론 파마슈티칼스 인코포레이티드 |
스테로이드 및 이의 단백질-접합체
|
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
|
|
KR102085798B1
(ko)
|
2016-12-28 |
2020-03-06 |
주식회사 인투셀 |
베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
|
|
KR20250008984A
(ko)
|
2017-05-18 |
2025-01-16 |
리제너론 파마슈티칼스 인코포레이티드 |
사이클로덱스트린 단백질 약물 접합체
|
|
WO2018213082A1
(en)
|
2017-05-18 |
2018-11-22 |
Regeneron Pharmaceuticals, Inc. |
Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
|
|
FI3635009T3
(fi)
|
2017-06-07 |
2026-04-07 |
Regeneron Pharma |
Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
|
|
MX2020004691A
(es)
|
2017-11-07 |
2020-08-20 |
Regeneron Pharma |
Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
|
|
CN112004557B
(zh)
|
2018-01-08 |
2024-07-30 |
里珍纳龙药品有限公司 |
类固醇类化合物及其抗体偶联物
|
|
MX2020011487A
(es)
|
2018-04-30 |
2020-12-07 |
Regeneron Pharma |
Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
|
|
CN112533951A
(zh)
|
2018-05-09 |
2021-03-19 |
里珍纳龙药品有限公司 |
抗msr1抗体及其使用方法
|
|
EP3793591A1
(en)
|
2018-05-17 |
2021-03-24 |
Regeneron Pharmaceuticals, Inc. |
Anti-cd63 antibodies, conjugates, and uses thereof
|
|
US20210196834A1
(en)
*
|
2018-05-30 |
2021-07-01 |
Abbvie Stemcentrx Llc |
Anti-sez6 antibody drug conjugates and methods of use
|
|
MA53455B1
(fr)
|
2018-11-20 |
2022-11-30 |
Regeneron Pharma |
Dérivés de bis-octahydrophénanthrène carboxamide et leurs conjugués protéiques destinés à être utilisés en tant qu'agonistes de lxr
|
|
MA53765B2
(fr)
|
2018-12-21 |
2025-04-30 |
Regeneron Pharmaceuticals, Inc. |
Tubulysines et conjugués tubulysines-protéines
|
|
JP7591503B2
(ja)
|
2018-12-21 |
2024-11-28 |
リジェネロン ファーマシューティカルズ，インク． |
リファマイシンアナログおよびその抗体薬物コンジュゲート
|
|
EP3908323A2
(en)
|
2019-01-08 |
2021-11-17 |
Regeneron Pharmaceuticals, Inc. |
Traceless linkers and protein-conjugates thereof
|
|
KR102735988B1
(ko)
|
2019-02-18 |
2024-12-03 |
일라이 릴리 앤드 캄파니 |
치료 항체 제제
|
|
US20220040319A1
(en)
|
2019-02-21 |
2022-02-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
|
|
JP2022530482A
(ja)
|
2019-05-02 |
2022-06-29 |
レゴケム バイオサイエンシズ， インク． |
トリス構造を有するリンカーを含むリガンド―薬物複合体
|
|
GB201910899D0
(en)
*
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
|
US11896682B2
(en)
|
2019-09-16 |
2024-02-13 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
|
|
US11814428B2
(en)
|
2019-09-19 |
2023-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-PTCRA antibody-drug conjugates and uses thereof
|
|
AU2021210987A1
(en)
|
2020-01-24 |
2022-08-04 |
Regeneron Pharmaceuticals, Inc. |
Protein-antiviral compound conjugates
|
|
IL295312A
(en)
|
2020-02-28 |
2022-10-01 |
Regeneron Pharma |
Bispecific antigen binding molecules that bind her2, and methods of use thereof
|
|
IL319200A
(en)
|
2020-04-16 |
2025-04-01 |
Regeneron Pharma |
Antibody-drug conjugates prepared using Diels-Alder compression methods
|
|
JP2023533218A
(ja)
|
2020-06-24 |
2023-08-02 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
ツブリシン及びタンパク質－ツブリシンコンジュゲート
|
|
KR20240038138A
(ko)
|
2020-07-13 |
2024-03-22 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
|
|
KR20230067632A
(ko)
*
|
2020-09-14 |
2023-05-16 |
암젠 인크 |
동결건조된 단백질 제형의 제조 방법
|
|
CA3191304A1
(en)
|
2020-09-14 |
2022-03-17 |
Amy Han |
Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
|
|
AU2021366691B2
(en)
|
2020-10-22 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-FGFR2 antibodies and methods of use thereof
|
|
EP4000635A1
(en)
*
|
2020-11-16 |
2022-05-25 |
Frank J. Hernandez |
Therapeutic-oligonucleotides activated by nucleases
|
|
MX2024000897A
(es)
|
2021-07-28 |
2024-02-06 |
Regeneron Pharma |
Conjugados de proteina y compuestos antivirales.
|
|
US20230414775A1
(en)
|
2021-12-29 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Tubulysins and protein-tubulysin conjugates
|
|
CA3241734A1
(en)
|
2022-01-12 |
2023-07-20 |
Amy Han |
Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
|
|
JP2025503700A
(ja)
|
2022-01-14 |
2025-02-04 |
レジェネロン ファーマシューティカルズ， インコーポレイテッド |
ベルカリンａ誘導体及びその抗体薬物複合体
|
|
EP4488290A1
(en)
|
2022-03-04 |
2025-01-08 |
ABTIS Co., Ltd. |
Method for increasing production yield of antibody-drug conjugate by using thiol-reactive additive
|
|
AU2023231305A1
(en)
|
2022-03-11 |
2024-09-12 |
Regeneron Pharmaceuticals, Inc. |
Anti-GLP1r antibody-tethered drug conjugates comprising GLP1 peptidomimetics and uses thereof
|
|
AU2023297610A1
(en)
|
2022-06-27 |
2025-01-09 |
Trioar, Inc. |
Novel linker compound and ligand-drug conjugate therefor
|
|
WO2024005460A1
(ko)
|
2022-06-27 |
2024-01-04 |
주식회사 트리오어 |
자가-희생기를 포함하는 화합물 및 이를 포함하는 리간드-약물 접합체
|
|
CA3261366A1
(en)
|
2022-07-21 |
2024-01-25 |
Firefly Bio, Inc. |
GLUCOCORTICOID RECEPTOR AGONISTS AND THEIR CONJUGATES
|
|
WO2024096564A1
(ko)
|
2022-11-01 |
2024-05-10 |
앱티스 주식회사 |
항-클라우딘18.2 항체를 포함하는 항체-약물 컨쥬게이트 및 이의 암에 대한 치료용도
|
|
CN120659785A
(zh)
|
2022-11-30 |
2025-09-16 |
里珍纳龙药品有限公司 |
Tlr7激动剂及其抗体-药物缀合物
|
|
IL321285A
(en)
|
2022-12-21 |
2025-08-01 |
Regeneron Pharma |
Topoisomerase I inhibitor prodrugs for ADC conjugates and a regimen for their use
|
|
EP4661914A1
(en)
|
2023-02-09 |
2025-12-17 |
Regeneron Pharmaceuticals, Inc. |
Antibody-drug conjugates via inverse electron demand diels-alder reactions
|
|
EP4705343A1
(en)
|
2023-05-02 |
2026-03-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
|
|
WO2025014533A1
(en)
|
2023-07-10 |
2025-01-16 |
Regeneron Pharmaceuticals, Inc. |
Anti-human cacng1 antibody-drug conjugates and uses thereof
|
|
US20250171516A1
(en)
|
2023-11-03 |
2025-05-29 |
Regeneron Pharmaceuticals, Inc. |
Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
|
|
WO2025117727A1
(en)
|
2023-11-29 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
|
|
WO2026020031A2
(en)
|
2024-07-18 |
2026-01-22 |
Novarock Biotherapeutics, Ltd. |
Cdh17 antibodies and uses thereof
|